At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 70 target
Drug / intervention
Chondroitin sulphate (Condrosan) +1 moredrug
Likely dose
Chondroitin sulphate (Condrosan) 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee
In Brief
A Phase 3 clinical trial evaluating Chondroitin sulphate (Condrosan) and Placebo for Synovitis and 3 related conditions. Completed, enrolled 70 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine the effect of a chondroitin sulphate conventional treatment on the degree of severity of synovitis, as measured by magnetic resonance in patients with knee OA with clinical synovitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSynovitis, Osteoarthritis, Joint Diseases, Muskuloskeletal Diseases
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartFeb 2008
Primary CompletionNov 2009
TodayJul 2026
First PostedJan 30, 2008
Enrollment StartFeb 1, 2008
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.4 years ago
Interventions
Chondroitin sulphate (Condrosan)drug
800 mg (two capsules of 400 mg each) taken once a day for one year
Placebodrug
Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day